Vanguard Group’s Kezar Life Sciences KZR Stock Holding History

Vanguard Group’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$2.15M	Buy	341,404 +73,238	+27%	+$427K	﹤0.01%	3539
2025 Q3	$1.05M	Sell	268,166 -8,062	-3%	-$33.1K	﹤0.01%	3776
2025 Q2	$1.27M	Hold	276,228	–	–	﹤0.01%	3675
2025 Q1	$1.35M	Buy	276,228 +2,117	+0.8%	+$12.8K	﹤0.01%	3621
2024 Q4	$1.84M	Hold	274,111	–	–	﹤0.01%	3584
2024 Q3	$2.12M	Hold	274,111	–	–	﹤0.01%	3543
2024 Q2	$1.64M	Sell	274,111 -35,311	-11%	-$268K	﹤0.01%	3623
2024 Q1	$2.79M	Buy	309,422 +3,074	+1%	+$28K	﹤0.01%	3493
2023 Q4	$2.9M	Buy	306,348 +2,291	+0.8%	+$20.1K	﹤0.01%	3466
2023 Q3	$3.62M	Buy	304,057 +750	+0.2%	+$13.3K	﹤0.01%	3381
2023 Q2	$7.43M	Buy	303,307 +2,095	+0.7%	+$54.5K	﹤0.01%	3117
2023 Q1	$9.43M	Sell	301,212 -1,386	-0.5%	-$80.2K	﹤0.01%	2965
2022 Q4	$21.3M	Buy	302,598 +3,277	+1%	+$243K	﹤0.01%	2595
2022 Q3	$25.8M	Buy	299,321 +55,602	+23%	+$5.4M	﹤0.01%	2523
2022 Q2	$20.2M	Buy	243,719 +20,911	+9%	+$1.84M	﹤0.01%	2639
2022 Q1	$37M	Buy	222,808 +33,666	+18%	+$4.83M	﹤0.01%	2449
2021 Q4	$31.6M	Sell	189,142 -2,543	-1%	-$287K	﹤0.01%	2609
2021 Q3	$16.6M	Buy	191,685 +1,206	+0.6%	+$79.8K	﹤0.01%	2962
2021 Q2	$10.3M	Buy	190,479 +3,927	+2%	+$223K	﹤0.01%	3181
2021 Q1	$11.1M	Buy	186,552 +5,868	+3%	+$343K	﹤0.01%	3094
2020 Q4	$9.43M	Buy	180,684 +24,235	+15%	+$1.35M	﹤0.01%	3028
2020 Q3	$7.57M	Buy	156,449 +1,197	+0.8%	+$57.2K	﹤0.01%	2933
2020 Q2	$8.04M	Buy	155,252 +28,145	+22%	+$1.42M	﹤0.01%	2873
2020 Q1	$5.54M	Buy	127,107 +91,517	+257%	+$3.72M	﹤0.01%	2931
2019 Q4	$1.43M	Sell	35,590 -1,633	-4%	-$50.3K	﹤0.01%	3540
2019 Q3	$1.22M	Sell	37,223 -2,836	-7%	-$137K	﹤0.01%	3594
2019 Q2	$3.09M	Sell	40,059 -539	-1%	-$83.8K	﹤0.01%	3335
2019 Q1	$7.2M	Buy	40,598 +23,562	+138%	+$4.64M	﹤0.01%	2992
2018 Q4	$4.02M	Buy	17,036 +13,780	+423%	+$3.37M	﹤0.01%	3159
2018 Q3	$698K	Sell	3,256 -744	-19%	-$130K	﹤0.01%	3795
2018 Q2	$692K	Buy	+4,000	New	+$698K	﹤0.01%	3775

Other funds holding KZR

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group's KZR Position: Q4 2025 in Review

Vanguard Group increased its Kezar Life Sciences (KZR) stake by 27% in Q4 2025, buying an estimated $427K and bringing the position to 341,404 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3539.

Vanguard Group first reported a position in KZR in Q2 2018 and has held it in 31 quarters since. The position peaked at $37M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2025.

Vanguard Group held 341,404 shares of Kezar Life Sciences worth $2.15M as of Q4 2025.
Vanguard Group bought 73,238 Kezar Life Sciences shares in Q4 2025, an estimated $427K.
Kezar Life Sciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3539 holding.
Vanguard Group first reported a position in Kezar Life Sciences in Q2 2018 and has held it in 31 quarters since.
Vanguard Group's Kezar Life Sciences position peaked at $37M in Q1 2022.
43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.